Antibody-drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure.

Breast · 2026 · PMC13094436 · PMID 41980521

Europe PMC DOI

hedged sentence

0.1200

closest p · 2.4× alpha

0.1200

boldest claim

The sentences

did not reach statistical significancep = 0.12not close (p > 0.1)

Median OS was 18.9 months (95% CI, 17.2–not reached) in T-DM1 pretreated patients and not reached in T-DM1 naive patients; the IPTW-weighted OS hazard ratio did not reach statistical significance (HR 1.80, 95% CI 0.86–3.79; p = 0.12).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.